Phase 1 clinical trials for sarcomas: The cutting edge

Current Opinion in Oncology

Volumn 23, Issue 4, 2011, Pages 352-360

  Subbiah, Vivek ^a,b   Kurzrock, Razelle ^a  

^a Department of Investigational Cancer Therapeutics   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

bone tumors; phase 1 trials; prognosis; sarcoma; sarcoma therapy; soft tissue sarcoma; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CEDIRANIB; CIXUTUMUMAB; CRIZOTINIB; DENOSUMAB; DOXORUBICIN; DULANERMIN; EVEROLIMUS; FIGITUMUMAB; GANITUMAB; IMATINIB; ISPINESIB; OMBRABULIN; PACLITAXEL; PAZOPANIB; R 1507; RAPAMYCIN; RG 7112; SERDEMETAN; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRABECTEDIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ALVEOLAR SOFT PART SARCOMA; CHONDROSARCOMA; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; NEUROECTODERM TUMOR; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CELL GRANULOMA; PRIORITY JOURNAL; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROTEIN KINASE INHIBITORS; SARCOMA;

EID: 79958820840     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283477a94     Document Type: Review

References (44)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Reynoso D, Subbiah V, Trent JC, et al. Neoadjuvant treatment of softtissue sarcoma: a multimodality approach. J Surg Oncol 2010; 101:327-333.
3. Thomas DM, Wagner AJ. Specific targets in sarcoma and developmental therapeutics. J Natl Compr Canc Netw 2010; 8:677-685; quiz 686.
4. Wardelmann E, Schildhaus HU, Merkelbach-Bruse S, et al. Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. Ann Oncol 2010; 21 (Suppl 7):vii265-vii269.
5. Reynoso D, Trent JC. Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments. Curr Opin Oncol 2010; 22:330-335.
6. Judson I. Targeted therapies in soft tissue sarcomas. Ann Oncol 2010; 21 (Suppl 7):vii277-vii280.
7. Marrari A, Trent JC, George S. Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. Curr Opin Oncol 2010; 22:336-341.
8. Kurzrock R, Patnaik A, Aisner J, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010; 16:2458-2465.
9. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-5807.
10. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010; 11:129-135.
11. Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28:2839-2846.
12. Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010; 28:5174-5181.
13. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363:1727-1733.
14. Chawla SP, Chua VS, Fernandez L, et al. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy- resistant sarcoma and osteosarcoma. Mol Ther 2009; 17:1651-1657.
15. Chu Q, Mita A, Forouzesh B, et al. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res 2010; 16:2656-2665.
16. Maurel J, Martins AS, Poveda A, et al. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to highdose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer 2010; 116:3692-3701.
17. Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009; 15:5902-5909.
18. Den Hengst WA, Van Putte BP, Hendriks JM, et al. Long-term survival of a phase I clinical trial of isolated lung perfusion with melphalan for resectable lung metastases. Eur J Cardiothorac Surg 2010; 38:621-627.
19. Souid AK, Dubowy RL, Ingle AM, et al. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer 2010; 55:1323-1328.
20. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011; 17: 871-879.
21. Rodon J, DeSantos V, Ferry RJ Jr, et al. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7:2575-2588.
22. Subbiah V, Anderson P, Lazar AJ, et al. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol 2009; 10:126-140.
23. Naing A, LoRusso P, Gupta S, et al. Dual inhibition of IGFR and mTOR pathways. J Clin Oncol (Meeting Abstracts) 2010; 28 (15 Suppl):3007.
24. Subbiah V, Naing A, Brown RE, et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitor: response and resistance signatures. Connective Tissue Oncology Society Proceedings. Paris, France; 2010. Abstract no. 898424.
25. Subbiah V, Naing A, Brown RE, et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitor: response/resistance signatures. PLoS One 2011; 6:e18424.
26. Gardner K, Judson I, Leahy M, et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 2009; 27:15s (suppl; abstr 10523).
27. Thornton KA. Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Core Evid 2010; 4:191-198.
28. Casali PG, Sanfilippo R, D'Incalci M. Trabectedin therapy for sarcomas. Curr Opin Oncol 2010; 22:342-346.
29. Bauer S, Yu LK, Demetri GD, et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006; 66: 9153-9161. (Pubitemid 44521135)
30. Wagner AJ, Morgan JA, Chugh R, et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. J Clin Oncol 2008; 26:2008 (May 20 suppl; abstr 10503).
31. Nilsson B, Nilsson O, Ahlman H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib: and then? Expert Opin Investig Drugs 2009; 18:457-468.
32. Jones RL, Olmos D, Thway K, et al. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol [Epub ahead of print].
33. Arkenau HT, Barriuso J, Olmos D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009; 27:2692-2696.
34. Subbiah V, Benjamin RS, Naing A, et al. Novel phase I clinical trials in sarcoma patients: The M. D. Anderson Cancer Center experience. J Clin Oncol (Meeting Abstracts) 2010; 28 (15 suppl):e13111.
35. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11:275-280.
36. Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011; 2011:483154.
37. Italiano A, Bianchini L, Gjernes E, et al. Clinical and biological significance of CDK4 amplification in well differentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009; 15:5696-5703.
38. Coindre JM, Pedeutour F, Aurias A. Well differentiated and dedifferentiated liposarcomas. Virchows Arch 2010; 456:167-179.
39. Anderson PM, Tomaras M, McConnell K. Mifamurtide in osteosarcoma: a practical review. Drugs Today (Barc) 2010; 46:327-337.
40. Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol 2010; 28:3101-3103.
41. Subbiah V, Trent JC, Kurzrock R. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol 2010; 28:e415.
42. Subbiah V, Anderson P. Targeted therapy of Ewing's sarcoma. Sarcoma 2011; 2010:686985.
43. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010; 28:4985-4995.
44. Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther 2007; 6:1175-1179. (Pubitemid 46711980)